Core Insights - The article highlights a groundbreaking clinical case study demonstrating the successful use of a 308-nm excimer laser in treating poikilodermatous mycosis fungoides (pMF), a rare subtype of cutaneous T-cell lymphoma [1][2][8] Company Overview - STRATA Skin Sciences, Inc. is a medical technology company focused on developing and marketing innovative products for dermatologic conditions, including the XTRAC excimer laser [1][12] - The company is actively working with the Centers for Medicare and Medicaid Services (CMS) to expand reimbursement codes for a wider range of conditions treated by the XTRAC laser [3] Clinical Study Details - The study, led by dermatology researchers at Tohoku University, is the first English-language report validating excimer laser therapy as a safe and effective treatment for pMF [2][3] - The case study involved a 50-year-old female patient with a 3-year history of progressive lesions, who showed marked improvement after treatment with the excimer laser [6][7] Treatment Efficacy - A systematic review published in 2022 indicated that 73.6% of patients with mycosis fungoides achieved a complete clinical response using the 308-nm excimer laser, with a low relapse rate of 5.7% [4] - The excimer laser offers a targeted treatment option that minimizes exposure to unaffected skin, contrasting with traditional therapies that require whole-body exposure [9][10] Market Implications - The successful application of the excimer laser in treating pMF could influence future treatment guidelines and improve patient quality of life in this rare disease population [11] - Japan is identified as a significant market for the XTRAC excimer laser, with local dermatologists pioneering new uses for the technology [3]